Hannah Slater | Authors


Assays of Intratumoral Heterogeneity May Predict RCCs Likely to Respond to PD-1 Blockade

January 21, 2021

“Our results suggest that low [intertumoral heterogeneity] is associated with increased response to anti–PD-1 immunotherapy in renal cell carcinoma through increased immune activity involving more neoantigens and less frequent immune evasion,” wrote the study authors, led by Xia Ran.

CASPIAN Update Supports Use of Durvalumab Plus Platinum-Etoposide in Frontline ES-SCLC

January 20, 2021

The ongoing phase 3 CASPIAN trial evaluating the use of intravenous durvalumab, with or without tremelimumab, added to platinum–etoposide for the first-line treatment of extensive-stage small cell lung cancer demonstrated improved overall survival versus chemotherapy alone.

Justin Gregg, MD, on the Use of the Mediterranean Diet in Men With Localized Prostate Cancer

January 19, 2021

The assistant professor of Urology at The University of Texas MD Anderson Cancer Center spoke about the results of a study which evaluated the use of the Mediterranean diet in men with localized prostate cancer on active surveillance.

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for HER2+ Gastric or GEJ Adenocarcinoma

January 15, 2021

The approval was based on results from the phase 2 DESTINY-Gastric01 trial which evaluated patients with HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma who had progressed on at least 2 prior regimens.

Scott Kopetz, MD, PhD, on the Results of the SWOG S1406 Trial

January 15, 2021

SWOG S1406 evaluated the use of irinotecan and cetuximab (Erbitux) with or without vemurafenib (Zelboraf) in patients with BRAF V600E-mutated metastatic colorectal cancer who had been previously treated with 1 or 2 regimens.

Receipt of IMRT Is a Predictive Factors for Survival in Oropharyngeal Cancer, Study Shows

January 13, 2021

A study found that patients without recurrence of their oropharyngeal cancer at 5 years who were treated with intensity-modulated radiation therapy and had less tobacco exposure experienced optimal survival, but still had poorer outcomes when compared with the general population.